Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials

Crit Care. 2020 Jul 20;24(1):449. doi: 10.1186/s13054-020-03163-3.

Manu Shankar-Hari^{1

2}, Lise Estcourt^{3

4}, Heli Harvala^{5

6}, David Roberts^{3

4}, David K Menon⁷; United Kingdom SARS-CoV-2 Convalescent Plasma Evaluation (SCoPE) Consortium

United Kingdom SARS-CoV-2 Convalescent Plasma Evaluation (SCoPE) Consortium:
Manu Shankar-Hari, Lise Estcourt, Heli Harvala, David Roberts, David K Menon

¹ School of Immunology & Microbial Sciences, Kings College London, 5th Floor, Southwark Wing, London, SE1 9RT, UK. [email protected].
² Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, 1st Floor, East Wing, St Thomas' Hospital, London, SE1 7EH, UK. [email protected].
³ NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Oxford, OX3 9BQ, UK.
⁴ Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
⁵ National Microbiology Services, NHS Blood and Transplant, Charcot Road, Colindale, NW9 5BG, UK.
⁶ Division of Infection and Immunity, University College of London, London, WC1E 6JF, UK.
⁷ Division of Anaesthesia, Department of Medicine, University of Cambridge, Box 93, Addenbrooke's Hospital, Cambridge, CB2 0NUI, UK.

No abstract available

Publication types